NASDAQ:JANX Janux Therapeutics (JANX) Stock Price, News & Analysis $43.99 +1.23 (+2.88%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$42.81▼$44.9750-Day Range$38.50▼$54.9852-Week Range$5.65▼$65.60Volume415,722 shsAverage Volume771,470 shsMarket Capitalization$2.28 billionP/E RatioN/ADividend YieldN/APrice Target$66.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Janux Therapeutics alerts: Email Address Janux Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside50.7% Upside$66.29 Price TargetShort InterestBearish10.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.92Based on 6 Articles This WeekInsider TradingSelling Shares$164.25 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.34) to ($1.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 starsMedical Sector505th out of 936 stocksPharmaceutical Preparations Industry231st out of 436 stocks 3.4 Analyst's Opinion Consensus RatingJanux Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageJanux Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Janux Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.44% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Janux Therapeutics has recently increased by 3.08%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldJanux Therapeutics does not currently pay a dividend.Dividend GrowthJanux Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for JANX. Previous Next 3.8 News and Social Media Coverage News SentimentJanux Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Janux Therapeutics this week, compared to 2 articles on an average week.Search Interest10 people have searched for JANX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows5 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Janux Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $164,250,000.00 in company stock.Percentage Held by Insiders35.40% of the stock of Janux Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Janux Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.34) to ($1.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Janux Therapeutics is -36.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Janux Therapeutics is -36.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJanux Therapeutics has a P/B Ratio of 5.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Janux Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Janux Therapeutics Stock (NASDAQ:JANX)Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Read More JANX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JANX Stock News HeadlinesJuly 24 at 1:30 AM | americanbankingnews.comJanux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 22, 2024 | businesswire.comJanux Therapeutics Announces Updates to Board of DirectorsJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 20, 2024 | investing.comJanux Therapeutics Inc (JANX)June 26, 2024 | seekingalpha.comJanux Therapeutics: Promising T-Cell Engager Platform In Cancer TherapyMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)May 13, 2024 | markets.businessinsider.comAnalyst Ratings For Janux TherapeuticsMay 8, 2024 | benzinga.comJanux Therapeutics Options Trading: A Deep Dive into Market SentimentJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 8, 2024 | finance.yahoo.comJanux Therapeutics Reports Narrower Q1 Loss, Misses Revenue EstimatesMay 7, 2024 | businesswire.comJanux Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 2, 2024 | msn.comJanux Therapeutics gains amid renewed takeover speculationApril 30, 2024 | finance.yahoo.comHere's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price StrengthApril 17, 2024 | investorplace.comTake the Money and Run: 3 Overbought Stocks to Sell ASAPApril 17, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - JANXApril 16, 2024 | msn.comJonesTrading Initiates Coverage of Janux Therapeutics (JANX) with Buy RecommendationApril 16, 2024 | msn.comJanux a new buy at Jones on lead assets for solid tumorsApril 16, 2024 | investorplace.comThese 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?See More Headlines Receive JANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JANX CUSIPN/A CIK1817713 Webwww.januxrx.com Phone858-751-4493FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$66.29 High Stock Price Target$100.00 Low Stock Price Target$47.00 Potential Upside/Downside+50.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,290,000.00 Net Margins-762.92% Pretax Margin-762.92% Return on Equity-13.49% Return on Assets-12.37% Debt Debt-to-Equity RatioN/A Current Ratio62.09 Quick Ratio62.09 Sales & Book Value Annual Sales$8.08 million Price / Sales282.29 Cash FlowN/A Price / Cash FlowN/A Book Value$7.46 per share Price / Book5.90Miscellaneous Outstanding Shares51,850,000Free Float33,496,000Market Cap$2.28 billion OptionableOptionable Beta3.58 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. David Alan Campbell Ph.D. (Age 64)President, CEO & Director Comp: $1.04MMr. Charles M. Winter (Age 55)Chief Technical Officer Comp: $590.4kMr. Byron Robinson J.D. (Age 59)Ph.D., Chief Strategy Officer Comp: $723kMr. Tighe M. Reardon C.F.A. (Age 48)CPA, Acting Chief Financial Officer Dr. Tommy Diraimondo Ph.D. (Age 38)Chief Scientific Officer Mr. James PenningtonGeneral CounselMs. Brenda Van VreeswykHead of Human ResourcesMr. Andy Hollman Meyer (Age 40)Chief Business Officer More ExecutivesKey CompetitorsDICE TherapeuticsNASDAQ:DICEPandion TherapeuticsNASDAQ:PANDPraxis Precision MedicinesNASDAQ:PRAXScholar RockNASDAQ:SRRKIGM BiosciencesNASDAQ:IGMSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 66,340 shares on 7/26/2024Ownership: 0.222%Summit Securities Group LLCBought 700 shares on 7/26/2024Ownership: 0.001%SG Americas Securities LLCBought 34,664 shares on 7/12/2024Ownership: 0.067%DNB Asset Management ASBought 5,273 shares on 7/5/2024Ownership: 0.010%Ventures Xi L.P. AvalonSold 677,279 sharesTotal: $37.08 M ($54.75/share)View All Insider TransactionsView All Institutional Transactions JANX Stock Analysis - Frequently Asked Questions How have JANX shares performed this year? Janux Therapeutics' stock was trading at $10.73 on January 1st, 2024. Since then, JANX shares have increased by 310.0% and is now trading at $43.99. View the best growth stocks for 2024 here. How were Janux Therapeutics' earnings last quarter? Janux Therapeutics, Inc. (NASDAQ:JANX) issued its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.05. The firm earned $1.25 million during the quarter, compared to analysts' expectations of $0.98 million. Janux Therapeutics had a negative net margin of 762.92% and a negative trailing twelve-month return on equity of 13.49%. When did Janux Therapeutics IPO? Janux Therapeutics (JANX) raised $152 million in an initial public offering (IPO) on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager. Who are Janux Therapeutics' major shareholders? Top institutional shareholders of Janux Therapeutics include Bank of New York Mellon Corp (0.22%), SG Americas Securities LLC (0.07%), DNB Asset Management AS (0.01%) and Summit Securities Group LLC. Insiders that own company stock include Ra Capital Management, LP, Ventures Xi LP Avalon and Tighe Reardon. View institutional ownership trends. How do I buy shares of Janux Therapeutics? Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:JANX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JANX Stock Alerts